Mental Health Care Act, 2017: How to organize the services to avoid legal complications?

Math, SureshBada; Gowda, MaheshR; Sagar, Rajesh; Desai, NimeshG; Jain, Rajeev

doi:10.4103/indianjpsychiatry.indianjpsychiatry_743_21

Cited by 3 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the beginning, the functional capacity of the patients will be assessed as per the Mental Health Care Act, 2017 [ 26 ]. The socio-demographic characteristics (gender, age, and body mass index), lifestyle (diet, sleep, and exercise), addiction history (other than behavioral addiction), present medical history, present drug history, relevant family history of psychiatric and neurological diseases, and details of the present psychotic disorder (age of onset, duration, and the severity of present illness) will be assessed at baseline.…”

Section: Methodsmentioning

confidence: 99%

Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers

Basu,

Dutta,

Bagepally

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objectives The response to antipsychotic therapy is highly variable. Pharmacogenomic (PGx) factors play a major role in deciding the effectiveness and safety of antipsychotic drugs. A hybrid type 2 effectiveness-implementation research will be conducted to evaluate the clinical utility (safety and efficacy), cost-effectiveness, and facilitators and barriers in implementing PGx-assisted management compared to standard of care in patients with schizophrenia attending a tertiary care hospital in eastern India. Methods In part 1, a randomized controlled trial will be conducted. Adult patients with schizophrenia will be randomized (2: 1) to receive PGx-assisted treatment (drug and regimen selection depending on the results of single-nucleotide polymorphisms in genes DRD2, HTR1A, HTR2C, ABCB1, CYP2D6, CYP3A5, and CYP1A2) or the standard of care. Serum drug levels will be measured. The patients will be followed up for 12 weeks. The primary endpoint is the difference in the Udvalg for Kliniske Undersøgelser Side-Effect Rating Scale score between the two arms. In part 2, the cost-effectiveness of PGx-assisted treatment will be evaluated. In part 3, the facilitators and barriers to implementing PGx-assisted treatment for schizophrenia will be explored using a qualitative design. Expected outcome The study findings will help in understanding whether PGx-assisted management has a clinical utility, whether it is cost-effective, and what are the facilitators and barriers to implementing it in the management of schizophrenia. Trial registration The study has been registered with the Clinical Trials Registry–India (CTRI/2023/08/056210).

show abstract

Section: Methodsmentioning

confidence: 99%

Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers

Basu,

Dutta,

Bagepally

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Under this Act, every adult 'shall have a right to make an advance directive in writing' , specifying 'the way the person wishes to be cared for and treated for a mental illness,' 'the way the person wishes not to be cared for & treated' . An advanced directive is used only if the person ceases to have the capacity to make mental healthcare decisions and shall remain e ective till the person regains the capacity to make decisions [19][20][21][22].…”

Section: Provision Of Advanced Directivesmentioning

confidence: 99%

“…e nomination shall be made in writing on plain paper with the person's signature or thumb impression. e person who is appointed as nominated representative shouldn't be a minor, capable of ful lling his duties given to him under this act [19][20][21][22].…”

Section: Nominated Representativesmentioning

confidence: 99%

“…In India, where mental health professionals are scarce, families are o en the critical resource for PMI care due to the tradition of interdependence and concern for loved ones in times of need. e act would bene t from acknowledging and fostering the contribution of family members' support in providing care [20][21][22][23][24][25].…”

Section: Critical Assessment Of Mhca 2017mentioning

confidence: 99%

“…Mentally ill persons are to be given rightful access to work and stay in their community, enjoy an optimal level of autonomy and privacy, and lead a normal family life. [20][21][22][23] Despite the increasing need for mental health services in India, the public mental healthcare system remains woefully inadequate. According to the National Mental Health Survey (NMHS-2016), approximately 150 million Indians require active interventions for their psychological issues.…”

Section: Status Of Human Rights Of Mentally Ill People In India: An A...mentioning

confidence: 99%

See 2 more Smart Citations

Mental healthcare act, 2017: a critical analysis on the protection of rights of the people with mental illness

Bhattacharjee

2024

J. Ment. Health. Behav. Sci.

View full text Add to dashboard Cite

It's important to acknowledge that individuals, groups, and agencies often violate the human rights of individuals living with mental illness. However, it is crucial to recognize that these rights apply to all human beings, regardless of their race, sex, nationality, ethnicity, language, or religion. Human rights include the right to life and liberty, freedom from slavery, discrimination, and torture, freedom of speech and expression, as well as the right to work and education, among others. The Mental Health Care Act (MHCA) of 2017 has replaced the Mental Health Act (MHA) of 1987 in India to protect the rights and well-being of people with mental illness. The old Act was not su cient in protecting the rights of the mentally ill, even though it served its purpose when it was created. As time passed and the focus shifted to the rights of the mentally ill, the 1987 Act fell short. The new Act aims to make mental healthcare services more humane and aligned with human rights standards, incorporating some novel ideas not present in its predecessor. However, only time will tell how e ective these new ideas, concepts, and clauses will be in the Indian context. In this article, we will explore how the Mental Healthcare Act of 2017 safeguards the human rights of mentally ill people in India.

show abstract

Caveats of mental healthcare act-2017: Recommendation for amendments

Sutar

Singh

Basera

2023

Indian Journal of Psychiatry

View full text Add to dashboard Cite

Mental Health Care Act, 2017: How to organize the services to avoid legal complications?

Cited by 3 publications

References 22 publications

Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers

Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers

Mental healthcare act, 2017: a critical analysis on the protection of rights of the people with mental illness

Caveats of mental healthcare act-2017: Recommendation for amendments

Contact Info

Product

Resources

About